Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson`s Disease (PD) and related disorders that arise inside and outside of the brain. The company`s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Website: inhibikase.com



Growth: Good revenue growth rate >200%, there is acceleration compared to average historical growth rates 100.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -46 700.0%. On average the margin is decreasing steadily. Gross margin is high, +100.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of $0 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 48 674.0% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 140.7% higher than minimum and 64.3% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -2260.2x by EV / Sales multiple

Insiders: For the last 3 months insiders bought company shares on $3.0 mln (7.521% of cap.)

Key Financials (Download financials)

Ticker: IKT
Share price, USD:  (0.0%)1.95
year average price 1.9206  


year start price 3.1000 2025-01-08

max close price 3.2600 2025-02-20

min close price 1.4100 2025-12-02

current price 1.9500 2026-01-07
Common stocks: 27 510 077

Dividend Yield:  0.0%
EV / Sales: -1 864.5x
Margin (EBITDA LTM / Revenue): -46 700.0%
Fundamental value created in LTM:
Market Cap ($m): 54
Net Debt ($m): -26 156
EV (Enterprise Value): -26 102
Price to Book: 0.7x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-20globenewswire.com

Inhibikase Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock and Pre-Funded Warrants

2025-08-14globenewswire.com

Inhibikase Therapeutics Announces Second Quarter 2025 Financial Results and Highlights Recent Activity

2025-01-29reuters.com

Inhibikase Therapeutics stops Parkinson's drug development as it fails to show benefits in study

2024-11-19seekingalpha.com

Inhibikase: Potential To Improve Current Treatment Options For PAH Patients

2024-11-14globenewswire.com

Inhibikase Therapeutics Reports Third Quarter Financial Results and Highlights Recent Activity

2024-10-21globenewswire.com

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

2024-10-09globenewswire.com

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

2024-08-15seekingalpha.com

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

2024-08-14globenewswire.com

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

2024-06-17globenewswire.com

Inhibikase Therapeutics Completes Enrollment of the Phase 2 ‘201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-05-15 2024-03-27 2023-11-14 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-12
acceptedDate 2025-11-14 16:37:19 2025-08-14 17:06:24 2024-11-14 08:30:21 2024-08-14 16:14:00 2024-05-15 17:04:56 2024-03-27 16:05:36 2023-11-14 16:15:27 2023-08-14 16:07:30 2023-05-15 08:01:27 2023-03-31 07:10:42 2022-11-14 17:10:41 2022-08-12 16:33:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
revenue 0 0 0 0 0 1 79 569 116 410 64 521 123 440 7291 6552
costOfRevenue 23 688 24 157 0 6569 6568 6568 6568 159 204 0 0 0 0
grossProfit -23 688 -24 157 0 -6569 -6568 -6567 73 001 -42 794 64 521 123 440 7291 6552
grossProfitRatio 0 0 0 0 0 -6567 0.917 -0.368 1 1 1 1
researchAndDevelopmentExpenses 8M 5M 4M 3M 3M 3M 3M 5M 3M 3M 3M 3M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 6M 6M 2M 2M 2M 1M 2M 2M 2M 1M 2M 2M
otherExpenses 0 -358 420 0 0 0 89 685 0 0 -64 521 -63 566 -7291 -6552
operatingExpenses 13M 11M 6M 5M 5M 4M 5M 6M 5M 4M 5M 5M
costAndExpenses 13M 11M 6M 5M 5M 4M 5M 6M 5M 4M 5M 5M
interestIncome 838 093 916 755 49 410 90 927 132 725 225 626 173 677 424 435 0 55 917 18 536 0
interestExpense 0 0 0 0 0 -661 606 0 424 435 237 171 55 917 18 536 0
depreciationAndAmortization 23 688 24 158 6568 6569 6568 6568 6583 159 204 5043 -13 494 18 536 0
ebitda -12M -11M -6M -5M -5M -4M -5M -6M -5M -4M -4M -5M
ebitdaratio 0 0 0 0 0 -4M -59.851 -51.913 -72.998 -35.227 -616.454 -708.171
operatingIncome -13M -11M -6M -5M -5M -4M -5M -6M -5M -4M -5M -5M
operatingIncomeRatio 0 0 0 0 0 -4M -59.934 -53.281 -73.076 -35.118 -618.996 -708.171
totalOtherIncomeExpensesNet 1M 916 755 49 410 90 927 132 725 225 629 173 677 424 435 237 171 55 922 18 536 0
incomeBeforeTax -12M -10M -6M -5M -5M -4M -5M -6M -4M -4M -4M -5M
incomeBeforeTaxRatio 0 0 0 0 0 -4M -57.751 -49.635 -69.4 -34.665 -616.454 -708.171
incomeTaxExpense 0 0 0 0 2 1 0 0 -474 342 -111 834 -37 072 0
netIncome -12M -10M -6M -5M -5M -4M -5M -6M -4M -4M -4M -5M
netIncomeRatio 0 0 0 0 0 -4M -57.751 -49.635 -62.049 -33.759 -611.369 -708.171
eps -0.133 -0.11 -0.65 -0.66 -0.73 -0.68 -0.86 -1.11 -0.15 -0.17 -0.18 -0.18
epsdiluted -0.133 -0.11 -0.65 -0.66 -0.73 -0.68 -0.86 -1.11 -0.15 -0.17 -0.18 -0.18
weightedAverageShsOut 90M 90M 9M 8M 6M 6M 5M 5M 28M 25M 25M 25M
weightedAverageShsOutDil 90M 90M 9M 8M 6M 6M 5M 5M 28M 25M 25M 25M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-05-15 2024-03-27 2023-11-14 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-12
acceptedDate 2025-11-14 16:37:19 2025-08-14 17:06:24 2024-11-14 08:30:21 2024-08-14 16:14:00 2024-05-15 17:04:56 2024-03-27 16:05:36 2023-11-14 16:15:27 2023-08-14 16:07:30 2023-05-15 08:01:27 2023-03-31 07:10:42 2022-11-14 17:10:41 2022-08-12 16:33:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 38M 78M 913 420 3M 2M 9M 15M 2M 4M 7M 6M 32M
shortTermInvestments 39M 10M 2M 5M 7M 4M 2M 19M 22M 16M 21M 0
cashAndShortTermInvestments 77M 88M 3M 8M 10M 13M 17M 21M 26M 23M 27M 32M
netReceivables 0 0 0 0 0 0 0 79 604 64 521 39 881 13 842 6552
inventory 0 0 0 0 0 0 0 425 229 923 128 1M 0 0
otherCurrentAssets 1M 1M 946 457 662 787 1M 958 996 371 538 543 923 922 764 163 452 505 924 2M
totalCurrentAssets 79M 89M 4M 9M 11M 14M 18M 22M 28M 24M 28M 34M
propertyPlantEquipmentNet 0 58 605 186 772 223 997 260 264 295 599 330 030 363 615 534 752 565 175 594 824 43 089
goodwill 0 0 0 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0 0 0 0
longTermInvestments 0 0 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 1M -0 0 0 0 -1 0 -363 615 0 0 0 0
totalNonCurrentAssets 1M 58 605 186 772 223 997 260 264 295 598 330 030 363 615 534 752 565 175 594 824 43 089
otherAssets 0 0 0 0 0 1 0 0 0 0 0 0
totalAssets 80M 89M 4M 9M 11M 15M 18M 22M 28M 25M 29M 34M
accountPayables 620 528 3M 3M 1M 1M 646 767 734 561 754 146 959 078 1M 781 223 860 444
shortTermDebt 0 37 944 145 210 304 448 151 159 531 879 149 030 147 966 146 901 145 836 142 048 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 0 0 0 0 0 23 683 23 684
otherCurrentLiabilities 6M 6M 2M 2M 3M 2M 2M 2M 2M 2M 2M 4M
totalCurrentLiabilities 7M 9M 5M 4M 4M 3M 3M 3M 3M 4M 3M 4M
longTermDebt 0 0 0 25 606 58 330 90 124 121 013 149 971 178 110 205 451 232 020 0
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 0 -0 0 0 -1 0 0 0 0 0 -714 934 4M
totalNonCurrentLiabilities 0 -0 0 25 606 58 329 90 124 121 013 149 971 178 110 205 451 232 020 4M
otherLiabilities 0 0 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 0 37 944 145 210 177 830 58 330 90 124 270 043 297 937 325 011 351 287 374 068 0
totalLiabilities 7M 9M 5M 4M 4M 4M 3M 3M 3M 4M 3M 4M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 74 808 74 516 7464 7216 6477 6186 5361 5291 31 056 25 227 25 227 25 227
retainedEarnings -130M -118M -82M -77M -72M -67M -63M -58M -52M -48M -44M -39M
accumulatedOtherComprehensiveIncomeLoss -4189 -2944 1754 -1024 -1800 877 -143 -1714 165 822 104 718 26 828 0
othertotalStockholdersEquity 203M 198M 82M 82M 78M 78M 78M 78M 77M 69M 69M 69M
totalStockholdersEquity 73M 80M -530 591 5M 7M 11M 15M 19M 25M 21M 25M 30M
totalEquity 73M 80M -530 591 5M 7M 11M 15M 19M 25M 21M 25M 30M
totalLiabilitiesAndStockholdersEquity 80M 89M 4M 9M 11M 15M 18M 22M 28M 25M 29M 34M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 80M 89M 4M 9M 11M 15M 18M 22M 28M 25M 29M 34M
totalInvestments 39M 10M 2M 5M 7M 4M 2M 19M 22M 16M 21M 0
totalDebt 0 37 944 145 210 177 830 209 489 622 003 270 043 297 937 325 011 351 287 374 068 0
netDebt -38M -78M -768 210 -3M -2M -9M -15M -2M -4M -7M -5M -32M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT IKT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-14 2025-08-14 2024-11-14 2024-08-14 2024-05-15 2024-03-27 2023-11-14 2023-08-14 2023-05-15 2023-03-31 2022-11-14 2022-08-12
acceptedDate 2025-11-14 16:37:19 2025-08-14 17:06:24 2024-11-14 08:30:21 2024-08-14 16:14:00 2024-05-15 17:04:56 2024-03-27 16:05:36 2023-11-14 16:15:27 2023-08-14 16:07:30 2023-05-15 08:01:27 2023-03-31 07:10:42 2022-11-14 17:10:41 2022-08-12 16:33:16
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3 Q2
netIncome -12M -10M -6M -5M -5M -4M -5M -6M -4M -4M -4M -5M
depreciationAndAmortization 23 688 24 158 6568 6569 6568 6568 6583 159 204 5043 5042 0 0
deferredIncomeTax 0 0 0 0 0 -223 179 0 -663 268 0 0 0 0
stockBasedCompensation 0 4M 148 024 30 697 53 434 122 249 129 781 124 845 123 273 100 363 101 788 132 767
changeInWorkingCapital -2M 466 812 -590 583 -132 032 722 615 592 436 336 462 928 528 -2M 638 091 -1M 151 370
accountsReceivables 0 0 0 0 0 0 79 602 -15 083 -24 638 70 258 0 0
inventory 0 0 0 0 0 -249 443 249 443 0 0 0 0 0
accountsPayables -2M 911 832 453 434 396 434 479 267 -87 794 -19 585 -204 932 -192 095 369 950 -79 221 54 248
otherWorkingCapital -164 658 -445 020 -1M -528 466 243 348 680 230 27 002 1M 216 733 197 883 -1M 0
otherNonCashItems 3M -358 420 1M 0 -412 697 237 435 17 280 663 268 0 -20 818 22 499 0
netCashProvidedByOperatingActivities -11M -6M -5M -5M -4M -3M -4M -5M -6M -4M -6M -4M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 14 238 0 -14 238 0 200 166 -200 166 0
acquisitionsNet 0 0 0 0 0 -14 238 0 14 238 0 0 0 0
purchasesOfInvestments -39M 0 -1M -776 974 -8M -9M -2M 3M -22M -16M 0 0
salesMaturitiesOfInvestments 10M 10M 4M 3M 5M 7M 19M -365 655 16M 5M 0 0
otherInvestingActivites 0 0 0 0 -3M -2M 17M -14 238 0 16M -21M -43 089
netCashUsedForInvestingActivites -29M 10M 3M 3M -3M -2M 17M 3M -6M 5M -21M -43 089
debtRepayment 0 0 0 0 0 0 0 0 0 -248 911 0 0
commonStockIssued 250 932 150 181 954 3M 366 999 -138 104 70 -35 986 9M 44 142 0 0
commonStockRepurchased 0 0 0 0 0 35 986 0 -35 986 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites -385 062 31 621 0 30 608 -30 608 -138 104 70 35 986 0 0 0 -248 911
netCashUsedProvidedByFinancingActivities -134 130 31 771 181 954 3M 366 999 -138 104 70 -35 986 9M -204 769 0 0
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0 204 769 0 0
netChangeInCash -39M 4M -2M 733 109 -7M -6M 13M -2M -3M 1M -26M -4M
cashAtEndOfPeriod 38M 78M 913 420 3M 2M 9M 15M 2M 4M 7M 6M 32M
cashAtBeginningOfPeriod 78M 73M 3M 2M 9M 15M 2M 4M 7M 6M 32M 37M
operatingCashFlow -11M -6M -5M -5M -4M -3M -4M -5M -6M -4M -6M -4M
capitalExpenditure 0 0 -4 4 0 14 238 0 -14 238 0 200 166 -200 166 0
freeCashFlow -11M -6M -5M -5M -4M -3M -4M -5M -6M -3M -6M -4M
link Link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q2
2024-08-15 ET (fiscal 2024 q2)
2024 q1
2024-05-17 ET (fiscal 2024 q1)
2023 q4
2024-03-28 ET (fiscal 2023 q4)
2023 q3
2023-11-15 ET (fiscal 2023 q3)
2023 q2
2023-08-15 ET (fiscal 2023 q2)
2023 q1
2023-05-16 ET (fiscal 2023 q1)
2022 q4
2023-04-03 ET (fiscal 2022 q4)
2022 q3
2022-11-15 ET (fiscal 2022 q3)
2022 q2
2022-08-15 ET (fiscal 2022 q2)
2022 q1
2022-05-17 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-12-19 16:17 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-12-19 16:17 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-21 21:28 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-21 21:28 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-21 21:28 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-21 21:28 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-21 21:28 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-21 21:28 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-20 21:11 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 8
2025-11-20 21:11 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 10
2025-11-14 16:37 ET
Inhibikase Therapeutics, Inc. reported for 2025 q3
SEC form 8
2025-11-14 16:25 ET
Inhibikase Therapeutics, Inc. reported for 2025 q3
SEC form 8
2025-11-14 16:25 ET
Inhibikase Therapeutics, Inc. published news for 2025 q3
SEC form 10
2025-08-14 21:06 ET
Inhibikase Therapeutics, Inc. reported for 2025 q2
SEC form 8
2025-08-14 20:56 ET
Inhibikase Therapeutics, Inc. published news for 2025 q2
SEC form 8
2025-08-14 20:56 ET
Inhibikase Therapeutics, Inc. reported for 2025 q2
SEC form 8
2025-08-14 20:56 ET
Inhibikase Therapeutics, Inc. published news for 2025 q2
SEC form 10
2025-05-14 21:29 ET
Inhibikase Therapeutics, Inc. reported for 2025 q1
SEC form 10
2025-05-14 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2025 q1
SEC form 8
2025-05-14 00:00 ET
Inhibikase Therapeutics, Inc. published news for 2025 q1
SEC form 10
2025-03-27 20:19 ET
Inhibikase Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-27 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2024 q4
SEC form 10
2025-03-27 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2024 q4
SEC form 8
2025-03-27 00:00 ET
Inhibikase Therapeutics, Inc. published news for 2024 q4
SEC form 10
2024-11-14 08:30 ET
Inhibikase Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-11-14 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2024 q3
SEC form 10
2024-08-14 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2024 q2
SEC form 10
2024-05-15 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2024 q1
SEC form 10
2024-03-27 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2023 q4
SEC form 10
2023-11-14 16:15 ET
Inhibikase Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2023 q3
SEC form 10
2023-08-14 16:07 ET
Inhibikase Therapeutics, Inc. reported for 2023 q2
SEC form 10
2023-08-14 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2023 q2
SEC form 6
2023-07-17 17:29 ET
Inhibikase Therapeutics, Inc. published news for 2023 q2
SEC form 6
2023-06-29 12:15 ET
Inhibikase Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-06-28 07:08 ET
Inhibikase Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-05-15 08:01 ET
Inhibikase Therapeutics, Inc. reported for 2023 q1
SEC form 10
2023-05-15 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2023 q1
SEC form 6
2023-05-05 16:31 ET
Inhibikase Therapeutics, Inc. published news for 2023 q1
SEC form 6
2023-04-21 16:30 ET
Inhibikase Therapeutics, Inc. published news for 2023 q1
SEC form 10
2023-03-31 07:10 ET
Inhibikase Therapeutics, Inc. reported for 2022 q4
SEC form 10
2023-03-31 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2022 q4
SEC form 6
2023-03-22 16:04 ET
Inhibikase Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-13 17:26 ET
Inhibikase Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-03-06 16:55 ET
Inhibikase Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-01-26 16:02 ET
Inhibikase Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-01-25 09:00 ET
Inhibikase Therapeutics, Inc. published news for 2022 q4
SEC form 6
2023-01-24 16:27 ET
Inhibikase Therapeutics, Inc. published news for 2022 q4
SEC form 6
2022-11-17 16:30 ET
Inhibikase Therapeutics, Inc. published news for 2022 q3
SEC form 8
2022-11-17 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-14 17:10 ET
Inhibikase Therapeutics, Inc. reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2022 q3
SEC form 6
2022-11-07 16:01 ET
Inhibikase Therapeutics, Inc. published news for 2022 q3
SEC form 6
2022-09-16 16:09 ET
Inhibikase Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-09-06 17:06 ET
Inhibikase Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-09-01 17:30 ET
Inhibikase Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-08-15 17:12 ET
Inhibikase Therapeutics, Inc. published news for 2022 q2
SEC form 10
2022-08-12 16:33 ET
Inhibikase Therapeutics, Inc. reported for 2022 q2
SEC form 10
2022-08-12 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2022 q2
SEC form 6
2022-07-28 17:55 ET
Inhibikase Therapeutics, Inc. published news for 2022 q2
SEC form 6
2022-06-29 16:01 ET
Inhibikase Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-05-16 21:49 ET
Inhibikase Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-05-16 16:18 ET
Inhibikase Therapeutics, Inc. reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Inhibikase Therapeutics, Inc. reported for 2022 q1
SEC form 6
2022-05-02 17:06 ET
Inhibikase Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-21 16:33 ET
Inhibikase Therapeutics, Inc. published news for 2022 q1
SEC form 6
2022-04-21 16:19 ET
Inhibikase Therapeutics, Inc. published news for 2022 q1
SEC form 10
2022-03-31 16:12 ET
Inhibikase Therapeutics, Inc. published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Inhibikase Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-24 09:17 ET
Inhibikase Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-21 16:30 ET
Inhibikase Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-03-08 16:38 ET
Inhibikase Therapeutics, Inc. published news for 2021 q4
SEC form 6
2022-01-20 16:10 ET
Inhibikase Therapeutics, Inc. published news for 2021 q4
SEC form 10
2021-11-15 16:33 ET
Inhibikase Therapeutics, Inc. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Inhibikase Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-10-19 17:03 ET
Inhibikase Therapeutics, Inc. published news for 2021 q3
SEC form 6
2021-09-08 15:46 ET
Inhibikase Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-08-17 17:02 ET
Inhibikase Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-16 16:16 ET
Inhibikase Therapeutics, Inc. published news for 2021 q2
SEC form 10
2021-08-16 00:00 ET
Inhibikase Therapeutics, Inc. published news for 2021 q2
SEC form 6
2021-06-28 20:25 ET
Inhibikase Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-21 09:23 ET
Inhibikase Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-16 09:20 ET
Inhibikase Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-06-01 07:30 ET
Inhibikase Therapeutics, Inc. published news for 2021 q1
SEC form 10
2021-05-17 16:41 ET
Inhibikase Therapeutics, Inc. published news for 2021 q1
SEC form 10
2021-05-17 00:00 ET
Inhibikase Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-04-30 17:20 ET
Inhibikase Therapeutics, Inc. published news for 2021 q1
SEC form 6
2021-04-01 13:13 ET
Inhibikase Therapeutics, Inc. published news for 2021 q1
SEC form 10
2021-03-31 14:14 ET
Inhibikase Therapeutics, Inc. published news for 2020 q4
SEC form 6
2021-02-08 07:01 ET
Inhibikase Therapeutics, Inc. published news for 2020 q4
SEC form 6
2020-12-29 16:38 ET
Inhibikase Therapeutics, Inc. published news for 2020 q3
SEC form 6
2020-12-22 20:42 ET
Inhibikase Therapeutics, Inc. published news for 2020 q3
SEC form 6
2020-12-22 20:41 ET
Inhibikase Therapeutics, Inc. published news for 2020 q3
SEC form 6
2020-12-22 20:41 ET
Inhibikase Therapeutics, Inc. published news for 2020 q3
SEC form 6
2020-12-22 20:40 ET
Inhibikase Therapeutics, Inc. published news for 2020 q3
SEC form 6
2020-12-22 20:40 ET
Inhibikase Therapeutics, Inc. published news for 2020 q3
SEC form 6
2020-12-22 20:39 ET
Inhibikase Therapeutics, Inc. published news for 2020 q3